A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Roka Bioscience Inc (NASDAQ:ROKA) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on September 19, 2016 and NASDAQ:ROKA investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/14/2016 -- The Shareholders Foundation announced that a deadline is coming up on September 19, 2016 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Roka Bioscience Inc (NASDAQ:ROKA) between July 17, 2014 and March 26, 2015.
Investors who purchased a significant amount of shares of Roka Bioscience Inc (NASDAQ:ROKA) between July 17, 2014 and March 26, 2015, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call 858-779-1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Roka Bioscience Inc (NASDAQ:ROKA) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/roka-bioscience-inc-nasdaq-roka-investor-securities-class-action-lawsuit-12242014
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is September 19, 2016. The class action administrator for this case is Strategic Claims Services.
The lawsuit was originally filed in the U.S. District Court for the District of New Jersey against Roka Bioscience Inc over alleged violations of Federal Securities Laws by Roka Bioscience in connection with certain allegedly false and misleading statements made between July 17, 2014 and November 6, 2014. According to the complaint the plaintiff alleges on behalf of purchasers of Roka Bioscience Inc (NASDAQ:ROKA) common shares between July 17, 2014 and November 6, 2014, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that Roka Bioscience Inc 's initial public offering ("IPO") documents allegedly failed to disclose known trends and uncertainties about the drastic decline in demand for its Atlas instruments that existed at the time of the IPO.
Those who purchased shares of Roka Bioscience Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com